Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

Executives who treat capital allocation as a CEO-level strategic discipline are best positioned to thrive in a volatile and ...

June was a slower month on the pharma agency side, but were several hires worth reporting, as well as a couple of interesting appointments on the non-profit side.

Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer, persuading Cristian Massacesi, M.D., to ...

Roche’s move came against a backdrop of wider industry retreat from gene therapy, with Pfizer pulling its FDA-approved ...

Johnson & Johnson JNJ and Pfizer PFE rank among the world’s largest pharmaceutical companies, each with broad and diversified healthcare portfolios. J&J operates primarily through its pharmaceuticals ...

Using both liquid and tissue biopsies to guide targeted treatment may improve outcomes in patients with solid tumor malignancies.